Business, energy, technology, markets and global industry news from Business News Today

ROS1-positive NSCLC

PharmaDeviceNews ROS1-positive NSCLC
Representative image: GSK’s $10.6 billion Nuvalent deal puts precision lung cancer therapies in focus as Big Pharma races to secure late-stage oncology assets.
Pharma & Biotech

Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions

GSK is betting $10.6B on Nuvalent’s lung cancer drugs. The payoff now depends on FDA decisions, labels and oncology launch execution.

Read More
Pharma & Biotech

Can Thermo Fisher help Nuvation Bio scale Ibtrozi supply for ROS1-positive NSCLC?

Rare cancer drugs need more than FDA approval. Nuvation Bio’s Ibtrozi test now shifts to U.S. supply reliability and launch execution.

Read More